Capricor Therapeutics (CAPR) shares are having a good Monday, and it's not hard to see why. The FDA just told the company, in so many words, "We're not done with you yet."
The agency extended the PDUFA target action date for deramiocel, the company's cell therapy for Duchenne muscular dystrophy, to November 22. That's a three-month delay from the original date, but here's the thing: the FDA didn't issue a Complete Response Letter, which is the regulatory equivalent of a breakup. No request for more studies, no demand for additional data. Just a simple, "We need more time to think about this."
For investors, that's about as good as it gets when you're waiting on a drug approval. The stock is up 14.07% to $7.17 at the time of publication, according to market data.
The extension comes after Capricor submitted an amendment to its marketing application, part of ongoing discussions with the FDA following the July 2026 Advisory Committee meeting. The amendment includes 24-month open-label extension data from the pivotal Phase 3 HOPE-3 study, plus additional robustness analyses. The company also asked the FDA to consider a refined proposed indication focused on upper limb function, which was the primary endpoint of HOPE-3.
The FDA's Center for Biologics Evaluation and Research (CBER) accepted the amendment for review, classifying it as a major amendment. That classification is what triggered the three-month extension, giving the agency time to dig into the new information.
"With an additional year of follow-up from HOPE-3, we now have one of the most extensive clinical datasets evaluating upper limb function in Duchenne," said Linda Marbán, CEO of Capricor.
That's a confident statement, but it comes with some baggage. In July, the FDA's Advisory Committee voted 9-3 that the company failed to provide sufficient evidence supporting deramiocel's effectiveness. The panel echoed FDA staff concerns about post hoc changes to key analyses after the late-stage trial concluded. So the agency is clearly taking a hard look at the data, and the extension is not a guarantee of approval.
Still, the market seems to be reading the tea leaves favorably. The absence of a Complete Response Letter is a meaningful signal. It suggests the FDA is willing to consider the new data, rather than shutting the door entirely.
Analysts are split on the stock. The consensus rating is Buy, with an average price target of $38.25 across 10 analysts. But the range is wide: a high of $63.00 and a low of $2.00. Recent moves include Cantor Fitzgerald upgrading to Overweight and raising its forecast to $28.00 on August 14. On the flip side, Jones Trading downgraded to Hold on July 31, and Piper Sandler downgraded to Neutral, slashing its forecast to $2.00 on July 30.
That kind of divergence tells you how uncertain this situation is. The bulls see a drug that could be a game-changer for Duchenne patients. The bears see a company that has struggled to convince regulators of its own data.
On the momentum front, Capricor is not exactly setting the world on fire. The stock's momentum signal is bearish, with a score of 1.17, according to the MarketDash Edge scorecard. That means despite today's spike, the broader trend is still weak compared to the market. For traders, that often means the stock is more headline-driven than trend-driven, at least until sustained follow-through improves the momentum profile.
So what's the takeaway? The FDA's decision to extend the review is a positive, but it's not a win. It's a stay of execution, a chance for Capricor to make its case with new data. The next few months will be crucial, and investors will be watching closely to see if the agency is swayed by the additional evidence.
For now, the market is giving Capricor the benefit of the doubt. Whether that confidence is justified will become clearer by November 22.
